Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: jayhawk969 who wrote (4423)	8/8/2001 9:46:44 AM
From: Biomaven	Read Replies (1) \| Respond to of 52153

J.D., Actually it's more the market re-juggling the portfolio than myself. I still hold MLNM (it's my next biggest holding after those listed, followed (after a gap) by a number of stocks like OSIP, CELG, JNJ (from the AZA munch),FRX, ABGX, and ADRX). I did trim MLNM a bit, just because in this environment people are skeptical about the long-term, and MLNM is still expensive if you look only at the short and medium term. Other sales that I recall in the past few months have included GZMO (worried about the German kidney vaccine project), GERN (worried about the stem cell fuss), and I trimmed VRTX a little (same reason as MLNM). Purchases (mostly small) have been AGIX, AZN (partly to hedge my ADRX), INHL (looking cheapish after the fall but still very risky although the Shearwater acquisition helps), and some additions to KOSN and ITMN. Peter